Feed aggregator

Expanding the arsenal of drugs against COVID-19

World Pharma News - Mon, 12/12/2022 - 11:00
The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been devastating the entire world. While the vaccination program is advancing, drug treatments for COVID-19 are still highly important for those who become infected. Now, a team at Tokyo Medical and Dental University (TMDU), National Center for Global Health and Medicine (NCGM), Tohoku University, NCI/NIH, and Kumamoto University has designed and synthesized compounds that have the potential to be novel drugs targeting SARS-CoV-2.

Amgen to Buy Horizon in Biotech’s Biggest Deal of 2022

Biospace news - Mon, 12/12/2022 - 02:00
Amgen confirmed Monday it will acquire rare disease giant Horizon Therapeutics for $26.4 billion.

Affimed Redirects Focus to NK Combo in Rare Type of Lymphoma

Biospace news - Mon, 12/12/2022 - 02:00
Affimed will not seek accelerated approval for AFM13 as a monotherapy in advanced-stage relapsed/refractory peripheral T cell lymphoma.

Embattled Clovis Oncology Files for Chapt. 11, Sells Radioligand Therapeutic to Novartis

Biospace news - Mon, 12/12/2022 - 02:00
Clovis Oncology officially files for Chapter 11 bankruptcy.

Merck Officially Commences $1.36B Imago Buyout

Biospace news - Mon, 12/12/2022 - 02:00
Merck initiated a tender offer Monday to buy all outstanding shares of Imago Biosciences. This follows the November announcement of the buyout.

Ibrutinib Combos Target Hard-to-Treat CLL and MCL at ASH 2022

Biospace news - Mon, 12/12/2022 - 02:00
Combinations including Ibrutinib stood out in hard-to-treat hematological cancers at the 64th American Society of Hematology (ASH) annual meeting.

NASH: Wall Street’s Forgotten Mega Blockbuster Indication

Biospace news - Mon, 12/12/2022 - 02:00
Wall Street is no longer enamored with NASH drug developers.

FDA Action Alert: Mirati, Coherus/Shanghai Junshi, Gilead and More

Biospace news - Mon, 12/12/2022 - 02:00
As 2022 comes to its conclusion, the FDA has a handful of Prescription Drug User Fee Amendments still to wrap up. Here’s a look at that and more.

How to Get the Most Out of Your Recruiter Relationship

Biospace news - Mon, 12/12/2022 - 02:00
Teaming up with a recruiter can be a smart move in a tight job market or for job seekers looking for a specialized role. To help you in your job search, we've outlined how to get the best out of recruiters.

Bayer launches industry-first public database listing company's science collaborations and partnerships in the U.S.

World Pharma News - Fri, 12/09/2022 - 11:00
Bayer has announced the U.S. launch of the Bayer Science Collaboration Explorer (BSCE) as part of its ongoing efforts to enhance public trust in scientific innovations, processes, and R&D activities. The Explorer is a publicly accessible database where Bayer shares information on its science collaborations and new contracts with universities, public research institutions, and individuals.

Autolus Meets Phase II Acute Lymphoblastic Leukemia Endpoint

Biospace news - Fri, 12/09/2022 - 02:00
Autolus Therapeutics is calling the Phase II FELIX trial, assessing its next-generation CAR-T therapy obe-cel for leukemia, a win after an interim analysis revealed an overall remission rate of 70%.

ImmunoGen and Gilead Team Up to Target AML

Biospace news - Fri, 12/09/2022 - 02:00
ImmunoGen entered into a clinical collaboration deal with Gilead Sciences Friday to evaluate the safety and efficacy of two drugs that, when used in concert, have the potential to treat AML.

Setting the Stage for ASH 2022

Biospace news - Fri, 12/09/2022 - 02:00
At ASH 2022, established hematology leaders like AstraZeneca, Janssen and Merck will showcase new data, and new players like Vega Therapeutics will launch new programs.

With Two Wins at SABCS, AstraZeneca Continues Breast Cancer Rally

Biospace news - Fri, 12/09/2022 - 02:00
​​​​​​​AstraZeneca posted two mid-stage wins at the 2022 San Antonio Breast Cancer Symposium on Thursday, touting the efficacy of capivasertib and camizestrant against breast cancer.

UCB Reports Positive Pivotal for New Approach to Hidradenitis Suppurativa (Updated)

Biospace news - Fri, 12/09/2022 - 02:00
UCB shared positive top-line results Friday from two Phase III studies of bimekizumab for adults with moderate to severe hidradenitis suppurativa.

Structural studies offer "how-to" guide for designing cancer drugs

World Pharma News - Thu, 12/08/2022 - 13:00
To design drugs that stall the growth of aggressive cancers, it helps to know the structures of the proteins that are revving the cancers' engines.

In a series of three papers published in Proceedings of the National Academy of Sciences, Scripps Research scientists have illuminated the three-dimensional structure of phosphoinositide 3-kinase alpha (PI3Kα), a protein often mutated in cancer cells.

CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again

World Pharma News - Thu, 12/08/2022 - 11:00
24 - 26 October, 2023, Barcelona, Spain.
The global pharma industry was out in full force at CPHI Frankfurt in November with 40,405 executives from 167 countries visiting the 2022 edition of the world-leading pharma industry tradeshow, a huge 75% increase over the number of attendees in 2021. Final visitor numbers will be confirmed by independent auditors ABC in early 2023.

Novartis Secures Second Phase III PNH Win in as Many Months

Biospace news - Thu, 12/08/2022 - 02:00
Novartis reported Thursday that a Phase III trial of iptacopan met its primary endpoint in paroxysmal nocturnal hemoglobinuria (PNH) - the company's second win in this indication in as many months.

‘Dramatic’ Placebo Effect Trips Relmada’s MDD Hopeful for the Second Time

Biospace news - Thu, 12/08/2022 - 02:00
Relmada's investigational NDMA receptor channel blocker, REL-1017, failed to meet its primary endpoint in major depressive disorder in the Phase III RELIANCE I trial.